Last updated on June 2018

Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers


Brief description of study

The primary objectives in the dose escalation phase are to evaluate safety and pharmacokinetics (PK) in order to determine the selected dose level(s) for expansion of REGN3767 as monotherapy and in combination with REGN2810 in patients with advanced malignancies, including lymphoma. The primary objectives in the dose expansion phase are to assess preliminary anti-tumor activity of REGN3767 alone and in combination with REGN2810 (separately by cohort) as measured by objective response rate (ORR).

Clinical Study Identifier: NCT03005782

Contact Investigators or Research Sites near you

Start Over

The Angeles Clinic

Los Angeles, CA United States
  Connect »

Henry Ford Health Hospital

Detroit, MI United States
  Connect »

Stephenson Cancer Center

Oklahoma City, OK United States
  Connect »

Rhode Island Hospital

Providence, RI United States
  Connect »

Asan Medical Center

Seoul, Korea, Republic of
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.